Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dyne TherapeuticsDYN +0.95%34 Buyback Yield % is -12.12 as of Aug. 11, 2026. GuruFocus rates DYN with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 725 Biotechnology companies, Dyne Therapeutics ranks worse than 55.03% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Dyne Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DYN vs VKTX, CELC, RLAY: Buyback Yield % Comparison
For the Biotechnology subindustry, Dyne Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dyne Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dyne Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Dyne Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dyne Therapeutics (DYN) has a Buyback Yield % of -12.12 as of Aug. 11, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Dyne Therapeutics and its competitors. According to the industry distribution chart, Dyne Therapeutics ranks #399 out of 725 companies in the Biotechnology industry, placing it in the top 55%.
Is Dyne Therapeutics' Buyback Yield % too high?
Dyne Therapeutics' current Buyback Yield % is -12.12. Based on the distribution chart, Dyne Therapeutics ranks #399 out of 725 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Dyne Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Dyne Therapeutics' Buyback Yield % compare to VKTX and CELC?
According to the Biotechnology industry distribution chart, Dyne Therapeutics ranks #399 out of 725 companies for Buyback Yield %. This places Dyne Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Dyne Therapeutics and its competitors. Dyne Therapeutics's current Buyback Yield % is -12.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dyne Therapeutics stock overvalued right now?
Dyne Therapeutics (DYN) has a current Buyback Yield % of -12.12. The current Buyback Yield % is -12.12. Dyne Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Dyne Therapeutics (DYN), the current Buyback Yield % is -12.12 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
34GF Score
Get the complete analysis for DYN
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DYN has been successfully added to your 
